Eli Lilly reported third-quarter revenue that significantly surpassed Wall Street estimates, fueled by ongoing strong demand for its popular weight loss drug Zepbound and diabetes medication Mounjaro.
In Q3 2025, Lilly’s global revenue reached $17.60 billion, reflecting a 54% rise from Q3 2024.
The company attributed this growth to a 62% volume increase, partially offset by a 10% decline from lower realized prices. Revenue from key products increased to $11.98 billion, primarily driven by Mounjaro and Zepbound.
David A. Ricks, Lilly chair and CEO told investors, “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio. We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant)—marking key progress across our pipeline. We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico.”
Looking ahead, the pharmaceutical giant now forecasts fiscal 2025 revenue to range from $63 billion to $63.5 billion, an increase from the earlier estimate of $60 to $62 billion. Eli Lilly also anticipates full-year adjusted profit to range between $23 and $23.70 per share, up from its previous projection of $21.75 to $23 per share.
The company’s shares increased 5% in premarket trading Thursday after the announcement.
By CEO NA Editorial Staff
